My SciELO
Services on Demand
Article
Indicators
Cited by SciELO
Related links
Similars in SciELO
Share
Revista Habanera de Ciencias Médicas
On-line version ISSN 1729-519X
Abstract
MEJIA-ZAMBRANO, Henry. Effects of glucagon-like peptide-1 receptor antagonist in the treatment of patients with obesity and Type 2 diabetes mellitus. Rev haban cienc méd [online]. 2022, vol.21, n.3 Epub June 10, 2022. ISSN 1729-519X.
Introduction:
New drugs with novel mechanisms of action and fewer adverse effects have recently been discovered for the treatment of type 2 diabetes. Among them are glucagon-like peptide-1 analogues.
Objective:
To explain the existing evidence of the effects of treatment with glucagon-like peptide-1 receptor agonists in people with obesity and type 2 diabetes mellitus.
Material and Methods:
We conducted a systematic review that included studies on the effects of glucagon-like peptide -1 receptor agonists for the treatment of people older than 12 years with obesity and type 2 diabetes. A formal narrative synthesis of the collected data was performed, whereas a formal statistical synthesis was not performed. The quality of evidence for each outcome was determined according to the Grading of Recommendations Assessment, Development and Evaluation method.
Results:
The available evidence shows that glucagon-like peptide -1 receptor agonists achieved a greater reduction in body weight (-7,0 % vs -2 %) and glycosylated hemoglobin (HbA1c) (-0,40 % vs -0,10 %) compared to the placebo group. In addition, there was a greater reduction in abdominal waist circumference.
Conclusions:
The evidence analyzed shows that glucagon-like peptide -1 receptor agonists have beneficial effects in the treatment of people with obesity and diabetes, reducing body weight and glycemia values.
Keywords : GLP-1 receptor agonists; DM2; obesity; body weight; glycemia values.